Construction of an expression cassette with hTNF-α gene for transient expression of the gene in mammalian cells

Anticancer Research

Volumn 21, Issue 1 A, 2001, Pages 365-372

  Novakovic S ^a   Cegovnik U ^a   Menart, V ^a   Galvani, V ^a   Wraber, B ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

B 16 melalona; hTNF ; Tumor vaccine

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; PLASMID DNA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; EXPRESSION VECTOR; GENE CASSETTE; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE TRANSFER; IRRADIATION; MAMMAL CELL; MELANOMA CELL; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOSENSITIVITY; RECOMBINANT DNA TECHNOLOGY; RESTRICTION MAPPING;

ANIMALS; CANCER VACCINES; CLONING, MOLECULAR; GENETIC VECTORS; HUMANS; KINETICS; MELANOMA, EXPERIMENTAL; MICE; PLASMIDS; RESTRICTION MAPPING; TRANSFECTION; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035060756     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. New approaches to the immunotherapy of cancer
2. Lymphokines and cytokines as cancer treatment. Immunotherapy realized
3. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies
4. Regression of human metastatic renal cell carcinoma after vaccination with cell-dendritic cell hybrids
5. BCG immunotherapy of bladder cancer
6. Effectiveness of a simply designed tumor vaccine in prevention of malignant melanoma development
7. An effective tumor vaccine against malignant melanoma: Irradiated autologous tumor cells admixed with MVE-2
8. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity
9. Specificity and longevity of antitumor immune response induced by B7-transfected tumors
10. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors
11. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system
12. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte
13. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with newcastle disease virus (NDV)
14. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection
15. Specific and nonspecific immunity in the prevention of spontaneous tumors
16. A new era for cancer immunotherapy based on the genes that encode cancer antigens
17. Current approaches to gene therapy in oncology: Construction of tumor vaccines
18. Biological therapies for breast carcinoma: Concepts for improvement in survival
19. Genetically modified tumor vaccines - Where we are today
20. Vaccination against human cancers
21. Introduction of DNA into mammalian cells
22. DNA sequencing with chain-terminating inhibitors
23. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis
24. Cytotoxicity assays for tumor necrosis factor and lymphotoxin
25. Serum values of TNF-alpha and soluble TNF-R55 in melanoma patients
26. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells
27. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules
28. Tumour necrosis factor: Characterization at the molecular, cellular and in vivo level
29. Biology of disease. Tumour necrosis factor and interleukin-1: Cytokines with multiple overlapping biological activities
30. Tumour necrosis factor-α (TNF-α): Biological activities and mechanisms of action
31. Tumour necrosis factor (TNF)
32. Tumour necrosis cachexia, shock and inflammation: A common mediator
33. The role of tumour necrosis factor and nitric oxide in the acute cardiovascular response to endotoxin
34. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α
35. Regional administration of recombinant tumor necrosis factor-α in cancer, with special reference to melanoma
36. New TNF-α analogues: A powerful but less toxic biological tool against tumors
37. Transfection of mammalian cells by the methods of receptor mediated gene transfer and particle bombardment
38. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer
39. Murine cells transduced with the gene for tumor necrosis factor α. Evidence for paracrine immune effects of tumor necrosis factor against tumors
40. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants